Fibromyalgia Syndrome Clinical Trial
Official title:
A Pilot Study of the Effect of Ultraviolet Light on Pain in Persons With Fibromyalgia Syndrome
Verified date | October 2018 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
- To establish whether ultraviolet light exposure acutely reduces perceptions of pain in
patients with fibromyalgia.
- To establish whether a series of UV light exposures has a cumulative effect on
fibromyalgia pain.
Status | Completed |
Enrollment | 19 |
Est. completion date | September 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Fibromyalgia patients who meet the fibromyalgia criteria, and who have been diagnosed with fibromyalgia by a board certified rheumatologist. The fibromyalgia criteria {as defined by the American College of Rheumatology (ACR)} require the patient to have: at least 3 months of widespread pain defined as: bilateral; above and below the waist, including axial skeletal pain; and pain to palpation with 4kg of pressure at a minimum of 11 out of 18 predefined tender points. - Ideally, patients should not be taking medication for treatment of fibromyalgia, and they should not be taking psychoactive medications on an as needed basis for treatment of fibromyalgia. However, if patients are taking psychoactive or other medications for the treatment of fibromyalgia, then they should be on a stable dose, defined as no change in dosage in the 4 weeks prior to study enrollment. - Patients must agree to not partake in tanning bed UV exposure during the study. Exclusion Criteria: - Fitzpatrick skin type 1 ("never tan, always burn") - Past or present skin cancer - Current use of photosensitizing drugs (current use of photosensitizing drugs will be evaluated via a patient questionnaire at time of patient enrollment - see Appendix 1),, psychoactive medications (not a stable dose, defined as no change in dosage in the 4 weeks prior to study enrollment), or illicit drugs - Pregnant, planning to become pregnant, or breast feeding - Significant visual discrimination of UV versus non-UV conditions - Greater than 6 indoor tanning sessions over the past year - Concurrent photosensitive disease, positive antinuclear antibody test, positive anti-Smith antibody test, or positive anti-dsDNA test. |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain Relief Success Rates (Phase I) | Percentage of exposures that showed pain relief (2 point improvement in Likert scale) in the 11 point Likert scale. | 2 weeks | |
Primary | Pain Score- Likert Scale(Phase II) | Pain will be assessed on an 11-point pain scale where 0=no pain and 10=worst possible pain. A 30% improvement in reported pain will be considered a treatment "success. | 6 weeks | |
Secondary | Post-treatment Pain Scores- Likert Scale (Phase I) | As a secondary outcome, the post-treatment pain scores between the UV and non-UV exposures given on the first day the dose is given will be compared. Pain will be assessed on an 11-point pain Likert scale where 0=no pain and 10=worst possible pain | 2 weeks | |
Secondary | Pain Scores of the UV and Non-UV Exposure (Phase II) | The pain scores were assessed using a Likert Scale. Pain will be assessed on an 11-point pain Likert scale where 0=no pain and 10=worst possible pain. | 4 weeks post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05933486 -
Efficacy and Safety of Tongluo-Kaibi Tablet in Patients With Fibromyalgia Syndrome
|
Phase 4 | |
Completed |
NCT01642810 -
Online Acceptance-based Behavioural Treatment for Fibromyalgia
|
Phase 3 | |
Completed |
NCT00757679 -
Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran
|
Phase 2 | |
Completed |
NCT00757731 -
FMS European Long-Term Study
|
Phase 3 | |
Completed |
NCT01968772 -
Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT00401830 -
Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
|
Phase 2 | |
Completed |
NCT04517929 -
Effectiveness of Group Psychotherapy in Patients With Fibromyalgia Syndrome
|
N/A | |
Completed |
NCT06285045 -
Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression
|
N/A | |
Completed |
NCT03844412 -
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
|
Phase 2 | |
Completed |
NCT02800720 -
Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome
|
N/A | |
Not yet recruiting |
NCT01465477 -
Influenza Vaccination in Fibromyalgia Patients
|
N/A | |
Completed |
NCT00528710 -
Efficacy of S-Adenosylmethionine in Fibromyalgia
|
Phase 2 | |
Not yet recruiting |
NCT06147882 -
The Effect of Positive Psychotherapy Based Psychoeducation on Pain Perception With Fibromyalgia Syndrome
|
N/A | |
Completed |
NCT05381012 -
Fibromyalgia Syndrome on Patients With Chronic Migraine
|
N/A | |
Completed |
NCT00464737 -
The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.
|
Phase 2 | |
Completed |
NCT04426864 -
Efficacy of Different Types of Exercises in Women With Fibromyalgia Syndrome.
|
N/A | |
Completed |
NCT02881411 -
Self Soft Tissue Therapy for Fibromyalgia Syndrome
|
N/A | |
Completed |
NCT01389336 -
Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone
|
N/A | |
Not yet recruiting |
NCT01147263 -
Palpitations and Tachycardia in Fibromyalgia Syndrome
|
N/A | |
Completed |
NCT00222274 -
HRV Biofeedback in Fibromyalgia
|
N/A |